Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY: LLY )

829.42 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, Apr 23, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 445
Open 829.42
Bid (Size) 810.00 (1)
Ask (Size) 828.00 (1)
Prev. Close 829.42
Today's Range 829.42 - 829.42
52wk Range 677.09 - 972.53
Shares Outstanding N/A
Dividend Yield 0.72%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Edwards Lifesciences Delivers In-Line Sales, Narrow Profit Beat
Edwards Lifesciences stock was flat late Wednesday after the medtech company beat profit views and delivered in-line sales. 
Via Investor's Business Daily
Topics ETFs
Bristol Myers' Cobenfy Falls Short On Primary Endpoint In Phase 3 Schizophrenia Trial, Stock Slides
Bristol Myers' Cobenfy missed its primary endpoint in the Phase 3 ARISE trial but showed symptom improvement in certain subgroups. 
Via Benzinga

Performance

YTD
+6.60%
+6.60%
1 Month
-4.10%
-4.10%
3 Month
+10.01%
+10.01%
6 Month
-8.17%
-8.17%
1 Year
+11.23%
+11.23%

More News

Read More
Forget Zepbound: Eli Lilly Has Its Next Billion-Dollar Weight Loss Drug
Via The Motley Fool
Pony.ai Targets Robotaxi Mass Production From Mid-2025: But Retail Sentiment Falters
Via Stocktwits
Topics Artificial Intelligence Lawsuit
Exposures Artificial Intelligence Financial Legal
Eli Lilly Sues Four Telehealth Companies Selling Copies Of Its Weight-Loss Drug, Says Report: But Retail Stays Optimistic
Via Stocktwits
Topics Lawsuit
Exposures Financial Legal Product Safety
Boston Scientific Stock Jets 8% Higher On Solid Quarterly Beat, Hiked Guidance
Via Investor's Business Daily
Topics Retirement
Exposures Pension
Direxion's Eli Lilly-Focused Bull And Bear Funds Offer Speculative Alternatives
Via Benzinga
Trump Administration Considers Lowering US Drug Prices To International Levels: Report
Via Benzinga
Topics Government
Exposures Political
Is Eli Lilly Stock Going to $900? 1 Wall Street Analyst Thinks So.
Via The Motley Fool
Topics World Trade
Exposures Tariff
Novo Nordisk Investors Just Got Terrible News. Should You Sell the Stock?
Via The Motley Fool
Is Eli Lilly Stock a Buy?
Via The Motley Fool
Q1 Earnings Season Scorecard And Analyst Reports For Nvidia, Alphabet & Berkshire Hathaway
Via Talk Markets
Topics Stocks / Equities
Why Vertex Pharmaceuticals Was Such a Healthy Stock on Tuesday
Via The Motley Fool
Intuitive Surgical Plunges After Saying Tariffs Impact 'Could Be Material'
Via Investor's Business Daily
Topics Government World Trade
Exposures Political Tariff
Roche Plans $50 Billion US Investment Over 5 Years With 12,000 New Jobs
Via Benzinga
Eli Lilly Positioned To Dominate Obesity Market With Oral Option, Analyst Initiates With Confidence
Via Benzinga
9 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Novo Nordisk Just Leapfrogged Eli Lilly With A Weight-Loss Pill; Shares Pop
Via Investor's Business Daily
Exposures Product Safety
3 Relatively Safe Healthcare Growth Stocks You Can Buy and Hold
Via The Motley Fool
Topics Government
Exposures Political
Think It's Too Late to Buy Novo Nordisk? Here's the Biggest Reason Why There's Still Time.
Via The Motley Fool
Down 60%, Is This Growth Stock Too Cheap to Ignore?
Via The Motley Fool
Novo Nordisk's FDA Submission For Obesity Pill Gets Retail Traders Buzzing Amid Fierce Eli Lilly Rivalry
Via Stocktwits
Exposures Product Safety
Upcoming Pfizer Earnings Call Might Be Focused On Tariffs, Policy Risks And Obesity Pipeline
Via Benzinga
Topics Earnings
Exposures Financial
ETFs Last Week: Thematic ETFs Gleamed Against Market Gloom
Via Benzinga
Topics ETFs Economy
Exposures Interest Rates
Down 61%, Is Novo Nordisk Stock Worth Buying on the Dip?
Via The Motley Fool
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.